These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 282625)
1. Autosomal locus regulates inverse relationship between sialic acid content and capacity of mouse erythrocytes to activate human alternative complement pathway. Nydegger UE; Fearon DT; Austen KF Proc Natl Acad Sci U S A; 1978 Dec; 75(12):6078-82. PubMed ID: 282625 [TBL] [Abstract][Full Text] [Related]
2. Regulation by membrane sialic acid of beta1H-dependent decay-dissociation of amplification C3 convertase of the alternative complement pathway. Fearon DT Proc Natl Acad Sci U S A; 1978 Apr; 75(4):1971-5. PubMed ID: 273923 [TBL] [Abstract][Full Text] [Related]
3. Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membrane. Fearon DT Proc Natl Acad Sci U S A; 1979 Nov; 76(11):5867-71. PubMed ID: 293688 [TBL] [Abstract][Full Text] [Related]
4. An autosomal dominant gene regulates the extent of 9-O-acetylation of murine erythrocyte sialic acids. A probable explanation for the variation in capacity to activate the human alternate complement pathway. Varki A; Kornfeld S J Exp Med; 1980 Sep; 152(3):532-44. PubMed ID: 7411019 [TBL] [Abstract][Full Text] [Related]
5. Guinea pig erythrocytes, after their contact with influenza virus, acquire the ability to activate the human alternative complement pathway through virus-induced desialation of the cells. Lambré CR; Kazatchkine MD; Maillet F; Thibon M J Immunol; 1982 Feb; 128(2):629-34. PubMed ID: 6459381 [TBL] [Abstract][Full Text] [Related]
6. Activation of the alternative complement pathway with rabbit erythrocytes by circumvention of the regulatory action of endogenous control proteins. Fearon DT; Austen KF J Exp Med; 1977 Jul; 146(1):22-33. PubMed ID: 559720 [TBL] [Abstract][Full Text] [Related]
7. Surface-associated heparin inhibits zymosan-induced activation of the human alternative complement pathway by augmenting the regulatory action of the control proteins on particle-bound C3b. Kazatchkine MD; Fearon DT; Silbert JE; Austen KF J Exp Med; 1979 Nov; 150(5):1202-15. PubMed ID: 501288 [TBL] [Abstract][Full Text] [Related]
8. A molecular basis of activation of the alternative pathway of human complement. Austen KF; Fearon DT Adv Exp Med Biol; 1979; 120B():3-17. PubMed ID: 390986 [TBL] [Abstract][Full Text] [Related]
9. Antibody restores human alternative complement pathway activation by mouse erythrocytes rendered functionally deficient by pretreatment with pronase. Moore FD; Austen KF; Fearon DT J Immunol; 1982 Mar; 128(3):1302-6. PubMed ID: 6915957 [TBL] [Abstract][Full Text] [Related]
10. Determination of alternative pathway of complement activity in mouse serum using rabbit erythrocytes. Van Dijk H; Rademaker PM; Willers JM J Immunol Methods; 1980; 36(1):29-39. PubMed ID: 7204994 [TBL] [Abstract][Full Text] [Related]
11. Complement C3 convertase: cell surface restriction of beta1H control and generation of restriction on neuraminidase-treated cells. Pangburn MK; Müller-Eberhard HJ Proc Natl Acad Sci U S A; 1978 May; 75(5):2416-20. PubMed ID: 276881 [TBL] [Abstract][Full Text] [Related]
12. Discrimination between activators and nonactivators of the alternative pathway of complement: regulation via a sialic acid/polyanion binding site on factor H. Meri S; Pangburn MK Proc Natl Acad Sci U S A; 1990 May; 87(10):3982-6. PubMed ID: 1692629 [TBL] [Abstract][Full Text] [Related]
13. Activation of the alternative complement pathway due to resistance of zymosan-bound amplification convertase to endogenous regulatory mechanisms. Fearon DT; Austen KF Proc Natl Acad Sci U S A; 1977 Apr; 74(4):1683-7. PubMed ID: 266208 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of the function of activated properdin by squid chondroitin sulfate E glycosaminoglycan and murine bone marrow-derived mast cell chondroitin sulfate E proteoglycan. Wilson JG; Fearon DT; Stevens RL; Seno N; Austen KF J Immunol; 1984 Jun; 132(6):3058-63. PubMed ID: 6427331 [TBL] [Abstract][Full Text] [Related]
15. Membrane sialic acid on target particles modulates their phagocytosis by a trypsin-sensitive mechanism on human monocytes. Czop JK; Fearon DT; Austen KF Proc Natl Acad Sci U S A; 1978 Aug; 75(8):3831-5. PubMed ID: 278997 [TBL] [Abstract][Full Text] [Related]
16. Pathways of complement activation in membranoproliferative glomerulonephritis and allograft rejection. Fearon DT; Daha MR; Strom TB; Weiler JM; Carpenter CB; Austen KF Transplant Proc; 1977 Mar; 9(1):729-39. PubMed ID: 325806 [TBL] [Abstract][Full Text] [Related]
17. Human alternative complement pathway: membrane-associated sialic acid regulates the competition between B and beta1 H for cell-bound C3b. Kazatchkine MD; Fearon DT; Austen KF J Immunol; 1979 Jan; 122(1):75-81. PubMed ID: 762425 [No Abstract] [Full Text] [Related]
18. C3b deposition during activation of the alternative complement pathway and the effect of deposition on the activating surface. Pangburn MK; Schreiber RD; Müller-Eberhard HJ J Immunol; 1983 Oct; 131(4):1930-5. PubMed ID: 6225800 [TBL] [Abstract][Full Text] [Related]
19. Development and application of an enzyme-linked immunosorbent assay for the quantitation of alternative complement pathway activation in human serum. Mayes JT; Schreiber RD; Cooper NR J Clin Invest; 1984 Jan; 73(1):160-70. PubMed ID: 6418767 [TBL] [Abstract][Full Text] [Related]
20. Inhibition of the alternative pathway of human complement by structural analogues of sialic acid. Michalek MT; Mold C; Bremer EG J Immunol; 1988 Mar; 140(5):1588-94. PubMed ID: 3346543 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]